SMS Cell Therapy
Chronic Obstructive Pulmonary Disease (COPD)
Phase 1bActive
Key Facts
About SMSbiotech
SMSbiotech is a private, clinical-stage biotech founded in 2015 and based in San Diego, California. The company's core asset is its patented Small Mobile Stem (SMS) cell platform, which produces unique, scalable adult stem cells from human blood for systemic, off-the-shelf therapies. Its lead program for COPD has completed a Phase 1b trial showing early safety and efficacy signals, positioning the company to advance into U.S. Phase 2 development. SMSbiotech operates as a therapeutics company with in-house biomanufacturing capabilities but is currently pre-revenue.
View full company profileOther Chronic Obstructive Pulmonary Disease (COPD) Drugs
| Drug | Company | Phase |
|---|---|---|
| PUR0200 | Pulmatrix | Preclinical |
| Dupixent (dupilumab) | Regeneron | Phase 3 |
| REGEND001 | Regend | Phase 1 |
| COPD Trial | Well Pharma Medical Research | Not Specified |
| AN01 | AirNexis Therapeutics | Phase 2 |
| COPD Diagnostic/Prognostic Test | Oxford Cancer Analytics | Pre-clinical |
| dNerva Lung Denervation System / Targeted Lung Denervation (TLD) | Nuvaira | Phase 3 |
| LBP for COPD | Alveolus Bio | Preclinical |
| AstraZeneca Collaboration Programs | Ethris | Discovery/Pre-clinical |
| COPD Phenotyping & Progression Biomarkers | Thirona | Commercial/Validation |
| TEZSPIRE (tezepelumab) | Amgen | Phase 3 |
| Verekitug (UPB-101) | Upstream Bio | Phase 2 |